Riboflavin for Glutamate Reduction in Alcohol Withdrawal

Phase 2

• Conditions: Nutrition Disorders; Alcohol Withdrawal; Alcohol Use Disorder
• Interventions: Other: Placebo; Drug: Riboflavin

• Registration Number: NCT04232800
• Lead Sponsor: Oregon Health and Science University

Brief Summary

This RCT intends to investigate the use of oral Riboflavin (Vitamin B2) for reduction of blood glutamate levels in the setting of acute alcohol withdrawal. Participants will be patients admitted to an inpatient hospital unit diagnosed with acute alcohol withdrawal. In addition to receiving care as usual, they will be randomized to receive either 100mg TID riboflavin or an identically dosed placebo. The primary outcome measure will be blood glutamate levels. Secondary outcomes will include measures of alcohol withdrawal and alcohol craving. The investigators hypothesize that those in the riboflavin group will have lower blood levels of glutamate, as well as decreased symptoms of alcohol withdrawal.

Detailed Description

General Investigational Plan

Hypotheses:

1. Aim 1: Measure the impact of daily oral riboflavin supplementation on blood Glu levels.

Hypothesis 1: Patients receiving riboflavin will have significant reductions in blood Glu levels, as compared to placebo.

2. Aim 2: Observe the impact of oral riboflavin on CIWA-AR scale scoring. Hypothesis 2: Riboflavin will significantly reduce the active group's CIWA-AR scores, and will result in fewer symptom triggered benzodiazepine doses, as compared to placebo.

Plan: The proposed study would apply a recently identified method using vitamin B2 (riboflavin) to reduce excess brain Glu activity in veterans in acute alcohol withdrawal. This method of "glutamate scavenging", was identified in a 2018 as a way to reduce glutamate associated brain damage which typically occurs after stroke. When tested in human patients immediately following stroke, the intervention demonstrated efficacy through better structural and functional outcomes when compared to placebo. Improvements persisted at 3 months after the initial stroke, and were not associated with any known side effects. Administration of riboflavin quickly decreases Glu levels in both the blood and brain, as measured using chromatography and Magnetic Resonance Imaging (MRI), respectively. As riboflavin's Glu reducing properties have just been discovered, this method has only been applied to the treatment of stroke, and has yet to be studied outside of the field of neurology. Further, oral riboflavin has not been investigated as a method of glutamate reduction. The hyperglutamatergic state in patients with alcohol withdrawal provides one opportunity for such an investigation, one that may lead to future studies improving treatments of alcohol withdrawal. Chronic, as well as acute alcohol users have both elevated extracellular glutamate as well as changes to glutamate receptors and transporters. These changes appear play a role in the rewarding effects of alcohol, and contribute to the symptoms of withdrawal. A positive correlation exists between CSF levels of glutamate and the severity of alcohol dependence, and patients in acute withdrawal have measurably increased levels of glutamate in their peripheral blood. During early withdrawal, elevated glutamate levels have been observed in the hippocampus and anterior cingulate cortex, returning to normal 3 days after symptom resolution. Given this information, riboflavin may provide a safe, effective, and affordable intervention to normalize the hyperglutamatergic state associated with alcohol withdrawal. The proposed study would investigate this hypothesis in patients admitted to the inpatient psychiatry unit in acute alcohol withdrawal.

Methods: Participants would be recruited on the inpatient psychiatry unit as they were admitted. The primary teams/on call residents would be asked to page a study member if a patient was admitted on the standard protocol for alcohol withdrawal: the Clinical Institute Withdrawal Assessment for Alcohol-Revised (CIWA-Ar). The study coordinator would consent the patient, and they would be randomized to either the placebo or riboflavin group. They would then receive TID oral dosing of either 100mg riboflavin or placebo, in addition to treatment as usual. The primary outcome would be daily blood glutamate levels, obtained with the normal morning labs. Secondary outcomes would CIWA scores, number of symptom-triggered benzodiazepines given, anxiety, and alcohol craving scores (using standardized measures).

Study Timeline

• Study First Submitted: 2020-01-13
• Study First Submitted QC: 2020-01-16
• Study First Posted: 2020-01-18
• Status Verified: 2021-09
• Last Update Submitted: 2021-09-27
• Last Update Posted: 2021-09-29
• Study Start: 2021-12-01
• Primary Completion: 2022-08-25
• Study Completion: 2022-10-25

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

• Adult veterans ages 18-65
• Admitted to the inpatient psychiatric unit at the Portland VA
• Determine by admitting physician to be currently in or at risk of alcohol withdrawal during admission
• Placed on the CIWA-AR protocol
• Willing to provide informed consent/HIPAA authorization and accept randomization
• Willing to ingest three capsules/day
• Willing to provide daily blood samples H) Fluent in English

Exclusion Criteria

• Known allergy to ingredients of riboflavin, capsules, or placebo ingredients
• Taking any medication acting primarily on Glu receptors (e.g. memantine) or GABA receptors (benzodiazepines) at baseline
• Unable to swallow capsules
• Actively in withdrawal from substances other than alcohol
• Unable to provide full informed consent/HIPAA authorization

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	Participants in this group will receive inert placebo capsules TID during study participation.
Riboflavin	Riboflavin	Participants in this group will receive 100mg riboflavin TID during study participation.

Primary Outcome Measures

Name	Time	Method
Peripheral blood glutamate level, day 6	Will occur on day 6 of the study	measured using high performance liquid chromatography (HPLC)
Peripheral blood glutamate level, day 2	Will occur on day 2 of the study	measured using high performance liquid chromatography (HPLC)
Peripheral blood glutamate level, day 8	Will occur on day 8 of the study	measured using high performance liquid chromatography (HPLC)
Peripheral blood glutamate level at baseline	Will occur on the day of enrollment in the study	measured using high performance liquid chromatography (HPLC)
Peripheral blood glutamate level, day 4	Will occur on day 4 of the study	measured using high performance liquid chromatography (HPLC)
Peripheral blood glutamate level, day 10	Will occur on day 10 of the study	measured using high performance liquid chromatography (HPLC)

Secondary Outcome Measures

Name	Time	Method
Day 3: Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale scores	Will occur on the day 3 after randomization (if participant has not yet discharged from the hospital)	The CIWA-Ar scale is a measure used in standard of care treatment of alcohol withdrawal. It assesses severity of symptoms, and can be used to determine the need for supportive therapy (e.g. benzodiazepines).It will be collected as standard of care, and will be analyzed as a secondary outcome measure.Scores range from 0-67, with a higher number indicating increased symptoms of alcohol withdrawal.
Day 7: Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale scores	Will occur on the day 7 after randomization (if participant has not yet discharged from the hospital)	The CIWA-Ar scale is a measure used in standard of care treatment of alcohol withdrawal. It assesses severity of symptoms, and can be used to determine the need for supportive therapy (e.g. benzodiazepines).It will be collected as standard of care, and will be analyzed as a secondary outcome measure.Scores range from 0-67, with a higher number indicating increased symptoms of alcohol withdrawal.
Day 2: Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale scores	Will occur on the day 2 after randomization (if participant has not yet discharged from the hospital)	The CIWA-Ar scale is a measure used in standard of care treatment of alcohol withdrawal. It assesses severity of symptoms, and can be used to determine the need for supportive therapy (e.g. benzodiazepines).It will be collected as standard of care, and will be analyzed as a secondary outcome measure.Scores range from 0-67, with a higher number indicating increased symptoms of alcohol withdrawal.
Day 9: Generalized Anxiety Disorder - 7 (GAD7) scale	Will occur on the day 9 after randomization (if participant has not yet discharged from the hospital)	A standardized measure of anxiety over the previous 2 weeks. Scores range from 0-21, with a higher score indicating more symptoms of anxiety.
Baseline: The Alcohol Craving Questionnaire-Revised (ACQ-R)	Will occur on the day of enrollment in the study	A brief, reliable, and validated measure of alcohol craving. Scores range from 1-7 with higher scores indicating stronger alcohol cravings
Day 8: The Alcohol Craving Questionnaire-Revised (ACQ-R)	Will occur on the day 8 after randomization (if participant has not yet discharged from the hospital)	A brief, reliable, and validated measure of alcohol craving. Scores range from 1-7 with higher scores indicating stronger alcohol cravings
Day 10: The Daily Assessment of Symptoms -Anxiety (DAS-A)	Will occur on the day 10 after randomization (if participant has not yet discharged from the hospital)	A reliable and valid measure of anxiety which has been shown to detect reduction of anxiety symptoms within 24 hours. Scores range from 0-80, with a higher score indicating more symptoms of anxiety
Day 6: Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale scores	Will occur on the day 6 after randomization (if participant has not yet discharged from the hospital)	The CIWA-Ar scale is a measure used in standard of care treatment of alcohol withdrawal. It assesses severity of symptoms, and can be used to determine the need for supportive therapy (e.g. benzodiazepines).It will be collected as standard of care, and will be analyzed as a secondary outcome measure.Scores range from 0-67, with a higher number indicating increased symptoms of alcohol withdrawal.
Baseline: # of Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale triggered benzodiazepine administration	Will occur on the day of enrollment in the study	As part of standard of care for acute alcohol withdrawal, patients are administered benzodiazepines for symptoms if a clinician-determined threshold is met. That is, patients who are more symptomatic (higher CIWA-Ar) scores, receive more benzodiazepines. This data is collected as standard of care, but will be used as a secondary outcome for this study.
Day 9: # of Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale triggered benzodiazepine administration	Will occur on the day 9 after randomization (if participant has not yet discharged from the hospital)	As part of standard of care for acute alcohol withdrawal, patients are administered benzodiazepines for symptoms if a clinician-determined threshold is met. That is, patients who are more symptomatic (higher CIWA-Ar) scores, receive more benzodiazepines. This data is collected as standard of care, but will be used as a secondary outcome for this study.
Day 10: # of Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale triggered benzodiazepine administration	Will occur on the day 10 after randomization (if participant has not yet discharged from the hospital)	As part of standard of care for acute alcohol withdrawal, patients are administered benzodiazepines for symptoms if a clinician-determined threshold is met. That is, patients who are more symptomatic (higher CIWA-Ar) scores, receive more benzodiazepines. This data is collected as standard of care, but will be used as a secondary outcome for this study.
Baseline Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale scores	Will occur on the day of enrollment in the study	The CIWA-Ar scale is a measure used in standard of care treatment of alcohol withdrawal. It assesses severity of symptoms, and can be used to determine the need for supportive therapy (e.g. benzodiazepines).It will be collected as standard of care, and will be analyzed as a secondary outcome measure.Scores range from 0-67, with a higher number indicating increased symptoms of alcohol withdrawal.
Day 4: Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale scores	Will occur on the day 4 after randomization (if participant has not yet discharged from the hospital)	The CIWA-Ar scale is a measure used in standard of care treatment of alcohol withdrawal. It assesses severity of symptoms, and can be used to determine the need for supportive therapy (e.g. benzodiazepines).It will be collected as standard of care, and will be analyzed as a secondary outcome measure.Scores range from 0-67, with a higher number indicating increased symptoms of alcohol withdrawal.
Day 8: Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale scores	Will occur on the day 8 after randomization (if participant has not yet discharged from the hospital)	The CIWA-Ar scale is a measure used in standard of care treatment of alcohol withdrawal. It assesses severity of symptoms, and can be used to determine the need for supportive therapy (e.g. benzodiazepines).It will be collected as standard of care, and will be analyzed as a secondary outcome measure.Scores range from 0-67, with a higher number indicating increased symptoms of alcohol withdrawal.
Day 9: Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale scores	Will occur on the day 9 after randomization (if participant has not yet discharged from the hospital)	The CIWA-Ar scale is a measure used in standard of care treatment of alcohol withdrawal. It assesses severity of symptoms, and can be used to determine the need for supportive therapy (e.g. benzodiazepines).It will be collected as standard of care, and will be analyzed as a secondary outcome measure.Scores range from 0-67, with a higher number indicating increased symptoms of alcohol withdrawal.
Day 2: # of Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale triggered benzodiazepine administration	Will occur on the day 2 after randomization (if participant has not yet discharged from the hospital)	As part of standard of care for acute alcohol withdrawal, patients are administered benzodiazepines for symptoms if a clinician-determined threshold is met. That is, patients who are more symptomatic (higher CIWA-Ar) scores, receive more benzodiazepines. This data is collected as standard of care, but will be used as a secondary outcome for this study.
Day 3: # of Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale triggered benzodiazepine administration	Will occur on the day 3 after randomization (if participant has not yet discharged from the hospital)	As part of standard of care for acute alcohol withdrawal, patients are administered benzodiazepines for symptoms if a clinician-determined threshold is met. That is, patients who are more symptomatic (higher CIWA-Ar) scores, receive more benzodiazepines. This data is collected as standard of care, but will be used as a secondary outcome for this study.
Day 4: # of Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale triggered benzodiazepine administration	Will occur on the day 4 after randomization (if participant has not yet discharged from the hospital)	As part of standard of care for acute alcohol withdrawal, patients are administered benzodiazepines for symptoms if a clinician-determined threshold is met. That is, patients who are more symptomatic (higher CIWA-Ar) scores, receive more benzodiazepines. This data is collected as standard of care, but will be used as a secondary outcome for this study.
Day 10: Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale scores	Will occur on the day 10 after randomization (if participant has not yet discharged from the hospital)	The CIWA-Ar scale is a measure used in standard of care treatment of alcohol withdrawal. It assesses severity of symptoms, and can be used to determine the need for supportive therapy (e.g. benzodiazepines).It will be collected as standard of care, and will be analyzed as a secondary outcome measure.Scores range from 0-67, with a higher number indicating increased symptoms of alcohol withdrawal.
Day 8: # of Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale triggered benzodiazepine administration	Will occur on the day 8 after randomization (if participant has not yet discharged from the hospital)	As part of standard of care for acute alcohol withdrawal, patients are administered benzodiazepines for symptoms if a clinician-determined threshold is met. That is, patients who are more symptomatic (higher CIWA-Ar) scores, receive more benzodiazepines. This data is collected as standard of care, but will be used as a secondary outcome for this study.
Day 3: Generalized Anxiety Disorder - 7 (GAD7) scale	Will occur on the day 3 after randomization (if participant has not yet discharged from the hospital)	A standardized measure of anxiety over the previous 2 weeks. Scores range from 0-21, with a higher score indicating more symptoms of anxiety.
Day 5: Generalized Anxiety Disorder - 7 (GAD7) scale	Will occur on the day 5 after randomization (if participant has not yet discharged from the hospital)	A standardized measure of anxiety over the previous 2 weeks. Scores range from 0-21, with a higher score indicating more symptoms of anxiety.
Day 6: Generalized Anxiety Disorder - 7 (GAD7) scale	Will occur on the day 6 after randomization (if participant has not yet discharged from the hospital)	A standardized measure of anxiety over the previous 2 weeks. Scores range from 0-21, with a higher score indicating more symptoms of anxiety.
Day 8: Generalized Anxiety Disorder - 7 (GAD7) scale	Will occur on the day 8 after randomization (if participant has not yet discharged from the hospital)	A standardized measure of anxiety over the previous 2 weeks. Scores range from 0-21, with a higher score indicating more symptoms of anxiety.
Day 10: Generalized Anxiety Disorder - 7 (GAD7) scale	Will occur on the day 10 after randomization (if participant has not yet discharged from the hospital)	A standardized measure of anxiety over the previous 2 weeks. Scores range from 0-21, with a higher score indicating more symptoms of anxiety.
Day 7: The Alcohol Craving Questionnaire-Revised (ACQ-R)	Will occur on the day 7 after randomization (if participant has not yet discharged from the hospital)	A brief, reliable, and validated measure of alcohol craving. Scores range from 1-7 with higher scores indicating stronger alcohol cravings
Day 4: The Daily Assessment of Symptoms -Anxiety (DAS-A)	Will occur on the day 4 after randomization (if participant has not yet discharged from the hospital)	A reliable and valid measure of anxiety which has been shown to detect reduction of anxiety symptoms within 24 hours. Scores range from 0-80, with a higher score indicating more symptoms of anxiety
Day 6: The Daily Assessment of Symptoms -Anxiety (DAS-A)	Will occur on the day 6 after randomization (if participant has not yet discharged from the hospital)	A reliable and valid measure of anxiety which has been shown to detect reduction of anxiety symptoms within 24 hours. Scores range from 0-80, with a higher score indicating more symptoms of anxiety
Day 7: # of Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale triggered benzodiazepine administration	Will occur on the day 7 after randomization (if participant has not yet discharged from the hospital)	As part of standard of care for acute alcohol withdrawal, patients are administered benzodiazepines for symptoms if a clinician-determined threshold is met. That is, patients who are more symptomatic (higher CIWA-Ar) scores, receive more benzodiazepines. This data is collected as standard of care, but will be used as a secondary outcome for this study.
Day 2: Generalized Anxiety Disorder - 7 (GAD7) scale	Will occur on the day 2 after randomization (if participant has not yet discharged from the hospital)	A standardized measure of anxiety over the previous 2 weeks. Scores range from 0-21, with a higher score indicating more symptoms of anxiety.
Day 2: The Alcohol Craving Questionnaire-Revised (ACQ-R)	Will occur on the day 2 after randomization (if participant has not yet discharged from the hospital)	A brief, reliable, and validated measure of alcohol craving. Scores range from 1-7 with higher scores indicating stronger alcohol cravings
Day 3: The Alcohol Craving Questionnaire-Revised (ACQ-R)	Will occur on the day 3 after randomization (if participant has not yet discharged from the hospital)	A brief, reliable, and validated measure of alcohol craving. Scores range from 1-7 with higher scores indicating stronger alcohol cravings
Day 10: The Alcohol Craving Questionnaire-Revised (ACQ-R)	Will occur on the day 10 after randomization (if participant has not yet discharged from the hospital)	A brief, reliable, and validated measure of alcohol craving. Scores range from 1-7 with higher scores indicating stronger alcohol cravings
Baseline: The Daily Assessment of Symptoms -Anxiety (DAS-A)	Will occur on the day of enrollment in the study	A reliable and valid measure of anxiety which has been shown to detect reduction of anxiety symptoms within 24 hours. Scores range from 0-80, with a higher score indicating more symptoms of anxiety
Day 2: The Daily Assessment of Symptoms -Anxiety (DAS-A)	Will occur on the day 2 after randomization (if participant has not yet discharged from the hospital)	A reliable and valid measure of anxiety which has been shown to detect reduction of anxiety symptoms within 24 hours. Scores range from 0-80, with a higher score indicating more symptoms of anxiety
Day 3: The Daily Assessment of Symptoms -Anxiety (DAS-A)	Will occur on the day 3 after randomization (if participant has not yet discharged from the hospital)	A reliable and valid measure of anxiety which has been shown to detect reduction of anxiety symptoms within 24 hours. Scores range from 0-80, with a higher score indicating more symptoms of anxiety
Day 7: The Daily Assessment of Symptoms -Anxiety (DAS-A)	Will occur on the day 7 after randomization (if participant has not yet discharged from the hospital)	A reliable and valid measure of anxiety which has been shown to detect reduction of anxiety symptoms within 24 hours. Scores range from 0-80, with a higher score indicating more symptoms of anxiety
Day 5: The Alcohol Craving Questionnaire-Revised (ACQ-R)	Will occur on the day 5 after randomization (if participant has not yet discharged from the hospital)	A brief, reliable, and validated measure of alcohol craving. Scores range from 1-7 with higher scores indicating stronger alcohol cravings
Day 9: The Alcohol Craving Questionnaire-Revised (ACQ-R)	Will occur on the day 9 after randomization (if participant has not yet discharged from the hospital)	A brief, reliable, and validated measure of alcohol craving. Scores range from 1-7 with higher scores indicating stronger alcohol cravings
Day 4: The Alcohol Craving Questionnaire-Revised (ACQ-R)	Will occur on the day 4 after randomization (if participant has not yet discharged from the hospital)	A brief, reliable, and validated measure of alcohol craving. Scores range from 1-7 with higher scores indicating stronger alcohol cravings
Day 6: The Alcohol Craving Questionnaire-Revised (ACQ-R)	Will occur on the day 6 after randomization (if participant has not yet discharged from the hospital)	A brief, reliable, and validated measure of alcohol craving. Scores range from 1-7 with higher scores indicating stronger alcohol cravings
Day 5: The Daily Assessment of Symptoms -Anxiety (DAS-A)	Will occur on the day 5 after randomization (if participant has not yet discharged from the hospital)	A reliable and valid measure of anxiety which has been shown to detect reduction of anxiety symptoms within 24 hours. Scores range from 0-80, with a higher score indicating more symptoms of anxiety
Day 8: The Daily Assessment of Symptoms -Anxiety (DAS-A)	Will occur on the day 8 after randomization (if participant has not yet discharged from the hospital)	A reliable and valid measure of anxiety which has been shown to detect reduction of anxiety symptoms within 24 hours. Scores range from 0-80, with a higher score indicating more symptoms of anxiety
Day 9: The Daily Assessment of Symptoms -Anxiety (DAS-A)	Will occur on the day 9 after randomization (if participant has not yet discharged from the hospital)	A reliable and valid measure of anxiety which has been shown to detect reduction of anxiety symptoms within 24 hours. Scores range from 0-80, with a higher score indicating more symptoms of anxiety
Day 5: Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale scores	Will occur on the day 5 after randomization (if participant has not yet discharged from the hospital)	The CIWA-Ar scale is a measure used in standard of care treatment of alcohol withdrawal. It assesses severity of symptoms, and can be used to determine the need for supportive therapy (e.g. benzodiazepines).It will be collected as standard of care, and will be analyzed as a secondary outcome measure.Scores range from 0-67, with a higher number indicating increased symptoms of alcohol withdrawal.
Day 5: # of Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale triggered benzodiazepine administration	Will occur on the day 5 after randomization (if participant has not yet discharged from the hospital)	As part of standard of care for acute alcohol withdrawal, patients are administered benzodiazepines for symptoms if a clinician-determined threshold is met. That is, patients who are more symptomatic (higher CIWA-Ar) scores, receive more benzodiazepines. This data is collected as standard of care, but will be used as a secondary outcome for this study.
Day 6: # of Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale triggered benzodiazepine administration	Will occur on the day 6 after randomization (if participant has not yet discharged from the hospital)	As part of standard of care for acute alcohol withdrawal, patients are administered benzodiazepines for symptoms if a clinician-determined threshold is met. That is, patients who are more symptomatic (higher CIWA-Ar) scores, receive more benzodiazepines. This data is collected as standard of care, but will be used as a secondary outcome for this study.
Baseline: Generalized Anxiety Disorder - 7 (GAD7) scale	Will occur on the day of enrollment in the study	A standardized measure of anxiety over the previous 2 weeks. Scores range from 0-21, with a higher score indicating more symptoms of anxiety.
Day 4: Generalized Anxiety Disorder - 7 (GAD7) scale	Will occur on the day 4 after randomization (if participant has not yet discharged from the hospital)	A standardized measure of anxiety over the previous 2 weeks. Scores range from 0-21, with a higher score indicating more symptoms of anxiety.
Day 7: Generalized Anxiety Disorder - 7 (GAD7) scale	Will occur on the day 7 after randomization (if participant has not yet discharged from the hospital)	A standardized measure of anxiety over the previous 2 weeks. Scores range from 0-21, with a higher score indicating more symptoms of anxiety.